Can progressive and non-progressive behavioural variant frontotemporal dementia be distinguished at presentation?
- 1Prince of Wales Medical Research Institute, University of New South Wales, Sydney, Australia
- 2Department of Clinical Neurosciences, University of Cambridge, UK
- 3Department of Neurology, Father Muller Medical College, Mangalore, India
- 4Wessex Neurological Centre, Southampton University NHS Trust, Southampton, UK
- Professor J Hodges, Prince of Wales Medical Research Institute, Cnr Barker and Easy Street, Randwick, NSW 2031, Sydney, Australia; j.hodges{at}powmri.edu.au
- Received 25 September 2008
- Revised 17 December 2008
- Accepted 14 January 2009
- Published Online First 18 February 2009
Abstract
Background: Recent findings suggest that patients with behavioural variant frontotemporal dementia (bv-FTD) differ in their disease progression (progressive vs non-progressive patients). The current study investigates whether the two groups can be discriminated by their clinical features at first presentation.
Methods: Archival clinical data of the Early Onset Dementia Clinic, Cambridge, UK, were analysed for 71 patients with bv-FTD: 45 progressive and 26 non-progressive cases with more than 3 years of follow-up.
Results: The subgroups were largely indistinguishable on the basis of the presenting clinical features but could be distinguished on general cognitive (Addenbrooke’s Cognitive Examination-revised) and selected supportive diagnostic features (distractibility, stereotypic speech, impaired activities of daily living (ADLs) and current depression).
Conclusions: Progressive and non-progressive patients are difficult to differentiate on the basis of current clinical diagnostic criteria for FTD but a combination of general cognitive, executive dysfunction and impaired ADL measures appear to be the most promising discriminators.
Footnotes
-
Funding: This research was funded in part by an MRC program grant to JRH. JRH is supported by an Australian Research Council Federation Fellowship (FF0776229). OP is supported by a National Health and Medical Research Council of Australia Clinical Career Development Award Fellowship (#510184).
-
Competing interests: None.
-
Ethics approval: The study was approved by Addenbrooke’s Hospital Local Research Ethics Committee, Cambridge, UK.







